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Abstract 
Huntington’s disease (HD) is a progressive neurodegenerative illness that affects 2–9/100.000 of the general popula-
tion. The usual onset is at around age 35–40 years, but there were cases with onset above 55 years. The disease mani-
fests clinically with many neurological and psychiatric symptoms, leading in advanced phases to dementia, but cogni-
tive symptoms are frequently present much earlier in the disease course. HD is caused by an expanded polyglutamine 
stretch in the N-terminal part of a 350 kDa protein called huntingtin (HTT). This stretch is encoded by a trinucleotide 
CAG repetition in exon 1 of HTT. An expansion of greater than 36 repeats results in HD. The number of repeats is 
inversely correlated with the age of onset of motor symptoms, and disease onset during childhood or adolescence is 
associated with more than 60 CAG repeats. Mood disturbances may be one of the earliest symptoms of HD and may 
precede the onset of the motor pheno-type for almost 10 years. Neuropsychiatric symptoms may delay the appropri-
ate diagnosis of HD and have major implications for disease management, prognosis and quality of life for patients 
and families. This case study is about a 58 years old female patient with late identification of Huntington’s disease after 
two admissions to psychiatric inpatient units, for the treatment of behavioral disturbances.
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Background
Huntington’s disease (HD) is a progressive neurode-
generative illness, which was the first disorder that was 
diagnosed using only DNA markers [1]. HD is caused by 
an expansion of a trinucleotide (CAG) above 35 repeats 
that is inherited in an autosomal dominant manner, with 
100 % penetrance when the CAG expansion exceeds 40 
repeats and with incomplete penetrance between 36 and 
39 repeats [2]. HD affects 2–9/100.000 of the general 
population, and has the usual onset at around age 35–40. 
It manifests clinically by many neurological and psychi-
atric symptoms, leading in advanced phases to dementia, 
although noticeable cognitive disturbance is frequently 
present earlier in the disease [3].
HD is caused by an expanded polyglutamine stretch 
in the N-terminal part of a 350 kDa protein called hun-
tingtin (HTT). HTT is ubiquitously expressed and is 
implicated in several cellular functions including control 
of transcription, vesicular trafficking, ciliogenesis, and 
mitosis. This stretch is encoded by a trinucleotide CAG 
repetition in exon 1 of HTT. An expansion of greater 
than 39 repeats results in HD [4]. The number of repeats 
is inversely correlated with the age of onset of motor 
symptoms, and disease onset during childhood or adoles-
cence is associated with more than 60 CAG repeats [5]. 
Mood disturbances may one of the earliest symptoms of 
HD and may precede the onset of the motor phenotype 
for almost 10 years [6–8]. The cognitive symptoms have 
been shown to be present 15 years prior to the time HD 
diagnosis and are related to disease-specific cerebral vol-
ume loss [9]. Neuropsychiatric symptoms may delay the 
appropriate diagnosis of HD and have major implications 
for disease diagnosis, management, prognosis and quality 
of life for patients and families [10].
This case study is about a female patient diagnosed 
with HD after two admissions to psychiatric inpatient 
units, for the treatment of behavioral disturbances. Writ-
ten informed consent was obtained from the patient for 
Open Access
*Correspondence:  petru_ifteni@yahoo.com 
1 Faculty of Medicine, Transilvania University, Brasov, Romania
Full list of author information is available at the end of the article
Page 2 of 4Pascu et al. Int J Ment Health Syst  (2015) 9:33 
publication of this case report and any accompanying 
images. A copy of the written consent is available for 
review by the Editor-in-Chief of this journal.
Case report
The female patient, 58  years old, was brought to the 
psychiatric emergency service and hospitalized for 
psychomotor agitation, verbal and physical aggression 
towards family, destruction of objects, insomnia, mood 
lability, dysphoria, and marked irritability. There were 
no signs of hallucinations, delusions or formal though 
disorder, the patient denied suicidal ideas. Psychotic or 
mood disorder diagnoses were excluded. The general 
physical examination revealed choreiform movements 
of the upper and lower limbs and head with gait and 
speech disturbances. The patient’s family declared that 
these disturbances started 2  years ago, but the patient 
neglected them. The patient smoked 20 cigarettes/day, 
but did not use alcohol or any other psychoactive sub-
stance. The patient’s father died at the age of 61 after 
acute renal failure. The mother died at age of 70 after a 
cerebral stroke. The patient stated that before her moth-
er’s death she presented some abnormal movements of 
hands and head, but without any neurological examina-
tion. The patient’s daughter was advised to perform the 
genetic test, but she did not follow this recommenda-
tion at the time.
Her family reported that 12 months ago the patient had 
a short episode of loss of consciousness, without seizures, 
from which she spontaneously recovered and which was 
not investigated at all. Two years ago, the patient was 
hospitalized at another psychiatric unit for similar behav-
ioral symptoms considered at that time as an adjustment 
disorder. The neurological examination did not reveal 
pathological findings at that time. Thereafter, she was 
treated as an outpatient for mood symptoms that were 
considered to be part of a personality disorder.
Investigations
The routine admission blood work, including electro-
lytes, renal, hepatic and thyroid parameters as well as 
full blood count with differential, were all within normal 
limits. The neurological evaluation found high amplitude 
choreiform involuntary movements, dysarthria, mild 
bilateral ataxia, normal sensory and power examina-
tion, normal reflexes and mild cognitive impairment (27 
points on Mini Mental State Examination). The hospital 
protocol for psychological evaluation included beyond 
the MMSE the Raven Standard Progressive matrices for 
intelligence coefficient (IQ) and Wechsler’s Deterioration 
Index. The results were normal (IQ = 98 and a deteriora-
tion index less than 4 %). The EEG was normal, but the 
CT scan (without contrast) showed marked, predomi-
nantly frontal cortical atrophy, large sylvian valleys and 
increased size of the ventricular system.
Based on the clinical symptoms, a degenerative illness, 
such as Huntington’s disease, was suspected. Genetic 
testing for the HTT gene was performed for confirma-
tion and was analyzed by PCR amplification with spe-
cific primers, followed by capillary electrophoresis. For 
one allele, 43 CAG repeats were detected, and the second 
allele had 10 CAG repeats. Considering that presence of 
more than 39 CAG repeats is considered pathological, 
the conclusion of the genetic analysis was that the patient 
either already had Huntington’s disease or would develop 
it in the future.
After the genetic test results had been obtained, the 
patient was re-evaluated by the neurologist, who estab-
lished the definite diagnosis of Huntington’s disease, 
confirmed both on clinical and genetic grounds. She is 
currently treated with small doses of haloperidol (1 mg/
day) and clonazepam (2  mg/day) with good results 
regarding behavioral and movement symptoms.
Discussion
This case report is about a patient with late identifica-
tion of HD at age 58 in a female who was diagnosed for 
the first time during her second psychiatric hospitaliza-
tion for psychomotor agitation, aggression, and irritabil-
ity. The presence of choreiform movements prompted 
the genetic testing, which together with the clinical pic-
ture led to the definite diagnosis of HD, but her diag-
nosis was delayed by prominence of neuropsychiatric 
symptomatology.
The particularity of this case is the delayed diagnosis 
of HD due to psychiatric symptoms and relatively late 
onset of the illness, based on the history of first emerg-
ing abnormal involuntary movements after the age of 55, 
although the literature usually mentions that the most 
frequent age of onset is 35–40 years [11].
The onset of the illness was correlated with the begin-
ning of functional impairment, both professionally (she 
was early retired at age of 56) and socially (she and her 
husband divorced). The patient was not much aware of 
or impaired by the abnormal movements and she did not 
seek medical consultation, as she considered it to be “a 
nervous tic”. However, the symptom that required medi-
cal attention, mostly at her family’s repeated requests, 
was the behavioral disinhibition. Often, people with 
HD may show reduced awareness of physical and men-
tal changes in themselves [12]. The lack of awareness 
was also seen in this patient and is an important corol-
lary of HD that contributes to delays in help-seeking and 
reporting of newly emerging problems, further delaying 
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the clinical diagnosis and treatment of HD. In our case, 
although the CT scan showed relevant cortical atrophy, 
the cognitive impairment was mild, without presence of 
clinical criteria for a dementia diagnosis. The patient’s 
psychiatric abnormalities, mainly the behavioral disinhi-
bition, irritability and aggression were likely correlated 
with the predominantly frontal cortical atrophy. Given 
the comparatively late onset of HD, the low abnormal 
number of CAG repeats and mild cognitive dysfunction, 
it is reasonable to assume that the affected parent in this 
case was the patient’s mother who had been diagnosed 
with “cerebral circulatory insufficiency” [13]. Available 
data suggest that there is a tendency for the affected 
descendant to present a larger CAG repeat expansion, 
which is believed to be responsible for a more malignant 
course of the disease. While gene transmission from the 
father has been associated with a higher risk for the rigid-
akinetic type of HD with childhood onset [14], in women 
there is an equal risk of contraction or expansion of the 
CAG repeat [15].
There have been several studies showing that psychi-
atric symptoms may precede motor symptoms and the 
ultimate diagnosis of HD [16, 17]. However, in this case, 
abnormal movements seem to have preceded the psychi-
atric disturbances by at least 1 year, but it was the latter 
that led to clinical attention and ultimate diagnosis at 
least 2 years after the onset of the abnormal movements. 
This case also illustrates the need to educate psychiat-
ric care providers in recognizing potential neurological 
reasons for psychiatric presentations, as HD had been 
missed during the first hospitalization 1 year ago. A sus-
picion of HD requires the physician to request a genetic 
test for diagnostic confirmation and, in case of a definite 
diagnosis, to refer the patient for genetic consultation 
and counseling, considering that HD is currently incur-
able and that the descendants of affected parents have a 
50 % chance to inherit the disease [18].
Conclusions
Huntington’s disease is a rare condition which is fre-
quently underdiagnosed, especially early on in the dis-
ease. This situation is caused by lack of recognition of 
HD symptoms, which are often attributed to another 
disease by patients, family members and sometimes even 
physicians.
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